Nikhil Wagle

Nikhil Wagle

UNVERIFIED PROFILE

Are you Nikhil Wagle?   Register this Author

Register author
Nikhil Wagle

Nikhil Wagle

Publications by authors named "Nikhil Wagle"

Are you Nikhil Wagle?   Register this Author

52Publications

2696Reads

34Profile Views

MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance.

Cell Rep 2019 Mar;26(10):2667-2680.e7

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2019.02.023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449498PMC
March 2019

KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance.

Cancer Cell 2018 12 21;34(6):939-953.e9. Epub 2018 Nov 21.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA 02215, USA; The Eli and Edythe L Broad Institute of MIT and Harvard, Cambridge, MA 02139, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Ludwig Center at Harvard, Boston, MA 02215, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108183048
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2018.10.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310147PMC
December 2018

Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer.

J Clin Oncol 2018 02 3;36(6):543-553. Epub 2018 Jan 3.

Daniel G. Stover, Ohio State University Comprehensive Cancer Center, Columbus, OH; Heather A. Parsons, Gavin Ha, William T. Barry, Hao Guo, Atish D. Choudhury, Melissa E. Hughes, Deborah A. Dillon, Ann H. Partridge, Nikhil Wagle, Ian E. Krop, Todd R. Golub, Eric P. Winer, Sara M. Tolaney, and Nancy U. Lin, Dana-Farber Cancer Institute; Gad Getz, Massachusetts General Hospital, Boston; Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Gregory Gydush, Sarah C. Reed, Justin Rhoades, Denisse Rotem, Nikhil Wagle, Gad Getz, Todd R. Golub, and Viktor A. Adalsteinsson, Broad Institute of Harvard and Massachusetts Institute of Technology; and J. Christopher Love, Massachusetts Institute of Technology, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.0033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815405PMC
February 2018

Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations.

Cancer Cell 2018 02;33(2):173-186.e5

Center for Functional Cancer Epigenetics, Dana Farber Cancer Institute, Boston, MA 02210, USA; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02210, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02210, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2018.01.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813700PMC
February 2018

Multiplexed Elimination of Wild-Type DNA and High-Resolution Melting Prior to Targeted Resequencing of Liquid Biopsies.

Clin Chem 2017 Oct 5;63(10):1605-1613. Epub 2017 Jul 5.

Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1373/clinchem.2017.272849DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914173PMC
October 2017

Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments.

Curr Oncol Rep 2015 Apr;17(4):15

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-015-0438-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854397PMC
April 2015

mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses?

EBioMedicine 2015 Jan 26;2(1):2-4. Epub 2014 Dec 26.

Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States ; Dana Farber Cancer Institute, Boston, MA 02115, United States ; Broad Institute of MIT and Harvard, Cambridge, MA 02142, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2014.12.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484506PMC
January 2015

ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors.

Cancer Res 2014 Dec 15;74(23):7079-89. Epub 2014 Oct 15.

Dana-Farber Cancer Institute, Boston, Massachusetts. Broad Institute, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-2073DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300142PMC
December 2014

Response and acquired resistance to everolimus in anaplastic thyroid cancer.

N Engl J Med 2014 Oct;371(15):1426-33

From the Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School (N.W., E.M.V.A., N.G., R.I.H., D.J.K., P.A.J., L.A.G., J.H.L.), the Department of Medicine, Brigham and Women's Hospital and Harvard Medical School (N.W., E.M.V.A., Y.G., R.I.H., D.J.K., P.A.J., L.A.G., J.H.L.), the Departments of Pathology (J.A.B.) and Surgery (S.J.S., D.T.R.), Brigham and Women's Hospital, the Department of Medicine, Beth Israel Deaconess Medical Center (G.J.H.), and Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute (P.A.J.) - all in Boston; and Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard (N.W., E.M.V.A., A.A.-M., A.T.-W., M.R., G.G., D.J.K., S.L.C., D.M.S., L.A.G.), Whitehead Institute for Biomedical Research and the MIT Department of Biology (B.C.G., D.M.S.), and Howard Hughes Medical Institute, MIT (B.C.G., D.M.S.) - all in Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1403352DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4564868PMC
October 2014

Assessing the clinical utility of cancer genomic and proteomic data across tumor types.

Nat Biotechnol 2014 Jul 22;32(7):644-52. Epub 2014 Jun 22.

1] Graduate Program in Structural and Computational Biology and Molecular Biophysics, Baylor College of Medicine, Houston, Texas, USA. [2] Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. [3].

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nbt.2940
Publisher Site
http://dx.doi.org/10.1038/nbt.2940DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102885PMC
July 2014

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

Cancer Discov 2014 May 13;4(5):546-53. Epub 2014 Mar 13.

Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, 3Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; Departments of 4Medicine and 5Pathology, Brigham and Women's Hospital, Harvard Medical School; 6Division of Hematology/Oncology, Massachusetts General Hospital, Boston; 7Broad Institute of Harvard and MIT; 8Department of Biology, Whitehead Institute for Biomedical Research; 9Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts; and 10Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0353DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122326PMC
May 2014

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

Cancer Discov 2014 Jan 21;4(1):94-109. Epub 2013 Nov 21.

1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School; 2Department of Pathology, Massachusetts General Hospital Cancer Center, Boston; 3Broad Institute of MIT and Harvard; 4Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts; 5Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen; 6German Cancer Consortium (DKTK); 7Department of Dermatology, Heidelberg University Hospital, Heidelberg; 8Department of Dermatology and Allergy, Hannover Medical School, Hannover; 9Department of Dermatology, University of Wuerzburg, Wuerzburg; 10Department of Dermatology, Venerology and Allergology, University of Schleswig-Holstein Hospital, Kiel; 11Department of Dermatology and Allergology, Ludwig-Maximilian University, Munich; 12Department of Dermatology, Venerology and Allergy, Charité Universitätsmedizin Berlin, Humboldt University, Berlin; 13Department of Dermatology, University of Mainz, Mainz; 14University Medical Center, University of Tübingen, Tübingen, Germany; 15Department of Genome Sciences, University of Washington, Seattle, Washington; 16Department of Dermatology, University Hospital Zurich, Zurich, Switzerland; and 17First Department of Medicine, Medical School, University of Athens, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0617DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947264PMC
January 2014

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.

Cancer Discov 2014 Jan 21;4(1):61-8. Epub 2013 Nov 21.

1Department of Medical Oncology, Dana-Farber Cancer Institute; 2Department of Medicine, Brigham and Women's Hospital; 3Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston; 4Broad Institute of Harvard and MIT; and 5Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0631DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947296PMC
January 2014

Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.

Cancer 2013 Nov 23;119(21):3776-83. Epub 2013 Aug 23.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Centers for Outcomes and Policy Research and Psychosocial Epidemiology and Outcomes Research, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28288DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972000PMC
November 2013

Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium.

Genet Med 2013 Nov 24;15(11):860-7. Epub 2013 Oct 24.

1] Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA [2] Carolina Center for Genome Sciences, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA [3] Center for Genomics and Society, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA [4] Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/gim.2013.133DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935342PMC
November 2013

Clinical analysis and interpretation of cancer genome data.

J Clin Oncol 2013 May 15;31(15):1825-33. Epub 2013 Apr 15.

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/31/15/1825.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.48.7215
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.48.7215DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878102PMC
May 2013

Biomarker-based prediction of response to therapy for colorectal cancer: current perspective.

Am J Clin Pathol 2010 Sep;134(3):478-90

Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY 12208, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1309/AJCP2Y8KTDPOAORHDOI Listing
September 2010

Cardiac presentation of anaplastic large-cell lymphoma.

J Clin Oncol 2010 Jul 1;28(19):e314-6. Epub 2010 Jun 1.

Brigham and Women's Hospital; Dana Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.26.7583DOI Listing
July 2010

A p53-dependent checkpoint pathway prevents rereplication.

Mol Cell 2003 Apr;11(4):997-1008

Cancer Center, Department of Medicine, Boston University School of Medicine, 80 East Concord Street, Massachusetts 02118, USA.

View Article

Download full-text PDF

Source
http://ac.els-cdn.com/S1097276503000996/1-s2.0-S109727650300
Web Search
http://www.bumc.bu.edu/busm-pathology/files/publications/MOL
Web Search
http://dx.doi.org/10.1016/s1097-2765(03)00099-6DOI Listing
April 2003